0
United States Anti-Doping Agency Reauthorization Act of 2021
3/8/2023, 7:58 PM
Summary of Bill HR 172
The bill includes provisions to ensure that the USADA has the necessary resources to continue its important work in promoting clean and fair competition in sports. This includes funding for drug testing programs, education and outreach efforts, and research into new methods of detecting performance-enhancing substances.
Additionally, the bill includes measures to improve transparency and accountability within the USADA. This includes requirements for the agency to report regularly to Congress on its activities and finances, as well as provisions to ensure that athletes have access to a fair and impartial appeals process in cases of alleged doping violations. Overall, the United States Anti-Doping Agency Reauthorization Act of 2021 aims to support the USADA in its mission to protect the integrity of sports and ensure a level playing field for all athletes.
Congressional Summary of HR 172
United States Anti-Doping Agency Reauthorization Act of 2021
This bill authorizes appropriations for the U.S. Anti-Doping Agency (USADA) through FY2030.
The bill adds requirements that USADA
- be responsible for certifying in advance any testing conducted by international organizations under the World Anti-Doping Code for international amateur athletes and athletic competitions occurring within the jurisdiction of the United States; and
- promote a positive youth sport experience by using a portion of its funding to provide educational materials on sportsmanship, character building, and healthy performance for those participating in youth sports.
The bill requires any action taken by USADA to enforce a policy, procedure, or requirement against a person with respect to a violation of federal law, including an investigation, disciplinary action, sanction, or any other administrative action, to be carried out in a manner that provides due process protection.
The Department of Justice, the Department of Homeland Security, and the Food and Drug Administration must provide to USADA information relating to the prevention of the use of performance-enhancing drugs or the prohibition of performance-enhancing methods.


